← Back to Search

Other

RPT193 for Atopic Dermatitis

Verified Trial
Phase 2
Waitlist Available
Research Sponsored by RAPT Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 35 days
Treatment 4 months
Follow Up 42 months
Awards & highlights

Study Summary

This trial is testing a new drug to see if it can improve symptoms of atopic dermatitis.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 35 days
Treatment ~ 4 months
Follow Up ~42 months
This trial's timeline: 35 days for screening, 4 months for treatment, and 42 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical efficacy
Safety as measured by adverse events

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: RPT193 50 mgExperimental Treatment1 Intervention
RPT193 50 mg oral tablet administered daily for 16 weeks
Group II: RPT193 400 mgExperimental Treatment1 Intervention
RPT193 400 mg oral tablet administered daily for 16 weeks
Group III: RPT193 200 mgExperimental Treatment1 Intervention
RPT193 200 mg oral tablet administered daily for 16 weeks
Group IV: PlaceboPlacebo Group1 Intervention
Matching placebo oral tablet administered daily for 16 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RPT193
2019
Completed Phase 1
~110

Find a Location

Logistics

Other reimbursement is provided

Other forms of reimbursement are provided for this trial.

Who is running the clinical trial?

RAPT Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
590 Total Patients Enrolled

Media Library

Placebo (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05399368 — Phase 2
Atopic Dermatitis Patient Testimony for trial: Trial Name: NCT05399368 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor include individuals over the age of fifty-five?

"The cutoff age for participating in this trial is 75 years old, with the minimum age of entry set at 18."

Answered by AI

Can I partake in this medical study?

"To qualify for this medical trial, individuals must have a clinical diagnosis of atopic dermatitis and be between 18-75 years old. They also need to report moderate-to-severe signs of eczema covering 10% or more of their body surface area, an Eczema Area Severity Index (EASI) score greater than 16 and Validated Investigator Global Assessment (VIGA) above 3. Additionally, they should demonstrate inadequate response to topical treatments over the past month as well as confirmed negative results from COVID screening tests."

Answered by AI

Are there any open opportunities for individuals to take part in this scientific experiment?

"Affirmative. Clinicaltrials.gov confirms that recruitment is underway for this medical trial, which was initially posted on June 7th 2022 and recently modified on October 21st 2022. A total of 268 patients are needed to be recruited from 43 different sites."

Answered by AI

Is there any risk associated with utilizing RPT193 as a treatment option?

"Due to a lack of efficacy data, our team at Power has assigned RPT193 a safety score of 2 on the 1-3 scale. Nonetheless, there is some evidence indicating that this drug's safety profile can be trusted."

Answered by AI

What is the enrollment size of this clinical trial?

"RAPT Therapeutics, Inc. is making efforts to recruit 268 qualified individuals for this clinical trial and will do so through partnering sites like Acclaim Dermatology in Sugar Land, Texas or Skin Sciences PLLC in Louisville, Kentucky."

Answered by AI

What is the current scope of this trial's operational sites?

"Patients can access this trial at Acclaim Dermatology in Sugar Land, Texas, Skin Sciences PLLC in Louisville, Kentucky and Advanced Dermatology of the Midlands in Omaha, Nebraska. Other 43 sites are also available."

Answered by AI

Who else is applying?

What state do they live in?
New York
Alabama
Other
Florida
How old are they?
18 - 65
What site did they apply to?
Perseverance Research Center
Cahaba Dermatology and Skin Health Center
Driven Research LLC
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
1
3+
2

What questions have other patients asked about this trial?

How long do the visits take and how many weeks?
PatientReceived no prior treatments

Why did patients apply to this trial?

Time to fix the issue. I have not been able to get rid of my exema. I've tried dermatologist recommended rx. Not helping.
PatientReceived 2+ prior treatments
I have used 4 different cremes and nothing clears it up. My face is crusty most of the time.
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Most responsive sites:
  1. Driven Research LLC: < 24 hours
Typically responds via
Phone Call
Recent research and studies
clinicaltrials.govStudy
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
2022. "An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05399368.
~22 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top